February 25, 2011 | Filed under: Health,News | Posted by:
High-risk breast cancer patients continue to derive benefits from the drug Herceptin even four years after stopping treatment, but questions remain about the biologic therapy’s safety when given with chemotherapy.
Posted by
on February 25, 2011. Filed under Health, News.
You can follow any responses to this entry through the RSS 2.0.
You can leave a response or trackback to this entry
Posted by
on February 25, 2011. Filed under